This week, we continue our series on Orphan Drugs by looking at a few ways that pharmaceutical companies game the system, and shoehorn their drugs into qualifying for orphan drug status, and therefore greater patent protection. All these methods tend to translate to higher costs for consumers.
Sources can be found in the posts friend-of-the-show Nick Bagley has written on the subject: http://theincidentaleconomist.com/wordpress/tag/orphan-drugs/
John Green — Executive Producer
Stan Muller — Director, Producer
Aaron Carroll — Writer
Mark Olsen – Graphics
Meredith Danko – Social Media
And the housekeeping:
1) You can support Healthcare Triage on Patreon: http://vid.io/xqXr Every little bit helps make the show better!
2) Check out our Facebook page: http://goo.gl/LnOq5z
3) We still have merchandise available at http://www.hctmerch.com